Zorevunersen's Four-Year Data Lands as Stoke Slips 1.7%
Four-year open-label extension data on zorevunersen showed durable seizure reductions and continuing cognitive gains in Dravet syndrome patients. STOK still closed down 1.67%.

Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extension studies of zorevunersen, an investigational Dravet syndrome medicine, at the 16th European Epilepsy Congress, reporting durable seizure reductions and continuing cognition and behavior gains; STOK closed at 29.99, down 1.67%.
Stoke Therapeutics (STOK) and Biogen (BIIB) took four years of follow-up data on zorevunersen to the 16th European Epilepsy Congress, arguing that the investigational medicine does more than suppress seizures in Dravet syndrome — that it changes the course of the disease itself. The data came from open-label extension studies running on from the Phase 1/2a program, in which patients received zorevunersen on top of the anti-seizure medicines they were already taking.
According to the companies' presentation, reported by Financial Post, the four-year results showed substantial and durable reductions in seizures alongside continuing improvements in cognition and behavior. Newer analyses presented at the congress pointed to substantial reductions in the most severe seizure types — the category clinicians treat as the leading risk factor for sudden unexpected death in epilepsy.
Why the severe-seizure signal carries the most weight
Dravet syndrome is a genetic epilepsy that begins in infancy. Seizure counts are the standard endpoint in epilepsy trials because they are countable, but they are not what families and clinicians fear most. The severe convulsive seizure types are the ones associated with sudden unexpected death, and they are also the ones that existing anti-seizure medicines address least reliably. A reported reduction specifically in that subset is therefore a different claim from a reduction in total seizure frequency, and it is the claim most likely to matter to regulators weighing benefit against the burden of a chronically dosed therapy.
The second half of the message is the developmental one. Children with Dravet typically face cognitive and behavioral impairment that accumulates over years, and conventional treatment does not reverse it. The companies' framing — that improvements in cognition and behavior continued through four years of exposure rather than plateauing early — is what underpins the term "disease-modifying." It is also the hardest thing to demonstrate in an open-label extension, where there is no concurrent control arm and where the natural expectation for untreated patients has to be inferred rather than observed. Investors should read the four-year data as supportive and directional, not as the confirmatory evidence a randomized pivotal study is designed to produce.
What an open-label extension can and cannot settle
An open-label extension enrolls patients who have completed an earlier trial and keeps them on active treatment, with everyone — patients, families, investigators — aware of what is being given. That design is well suited to two questions: does the effect hold up over years, and does the safety profile deteriorate with cumulative dosing. Four years of continuous data speaks directly to both, which is why long-term extension results are routinely presented at clinical congresses even when the pivotal program is still running.
What the design cannot do is separate drug effect from expectation, from concurrent changes to background anti-seizure medicines, or from the tendency of the sickest patients to leave a study first. That is the gap a controlled pivotal trial exists to close. The practical value of the congress data is that it lowers the odds of an unpleasant surprise on durability or long-term tolerability — the two failure modes that have historically ended promising rare-epilepsy programs late.
How the market took it
The reaction was muted, and slightly negative for the smaller partner. STOK finished the session at 29.99, down 1.67% from a previous close of 30.50, having traded between 29.69 and 30.70. Biogen closed at 224.51, up 0.83% from 222.67, inside a 221.23 to 225.80 range. Those are the most recent traded prices, as of 20:00 GMT on Sept. 3, 2026; the market is closed.
Context matters for reading that. It was a broadly strong day for U.S. equities: the S&P 500 tracker closed at $773.17, up 1.05%; the Nasdaq 100 proxy at $717.67, up 1.19%; and the Dow tracker at $536.93, up 1.19%. Against a tape that rose across all three benchmarks, a decline in Stoke shares is a relative underperformance rather than a neutral drift — the kind of response that suggests the market had already priced in the general shape of long-term extension results and was looking for something else.
That is not unusual for congress data on a partnered asset. Extension results confirm what earlier readouts implied; they rarely reset a valuation on their own. The events that move a clinical-stage share price tend to be randomized data, regulatory decisions, and changes to the economics of the partnership itself.
The partnership question behind the data
Extension results confirm what earlier readouts implied; they rarely reset a valuation on their own.
Zorevunersen is being advanced jointly, with Biogen presenting alongside Stoke. For Biogen, a rare genetic epilepsy asset sits comfortably next to an established neurology franchise and represents a modest share of a large pipeline — which is why a positive congress presentation would not be expected to move the shares much in either direction. For Stoke, the same asset is closer to the center of the story, and the leverage runs the other way: a single program's progress carries far more of the equity value.
That asymmetry explains a good deal of the divergent price action, and it frames what to watch. Three things will decide whether the four-year data ends up looking like a milestone or a footnote:
- Whether the pivotal program reproduces the reduction in severe seizure types under randomized, controlled conditions rather than open-label follow-on.
- Whether the cognition and behavior improvements can be captured on endpoints regulators will accept as evidence of disease modification, not just as supportive secondary measures.
- Whether the long-term safety picture holds as cumulative exposure extends past the four-year mark now reported.
Rare disease programs in genetic epilepsy have a small addressable population and an unusually motivated patient community, which shortens enrollment and sharpens the pricing conversation later. The clinical case Stoke and Biogen made in Europe is that zorevunersen alters the trajectory of Dravet rather than managing its symptoms. The commercial case will be settled by whichever randomized dataset comes next — and, judging by Thursday's close, that is what the market is waiting for.
Key facts
- STOK last close: 29.99, -1.67% (as of 20:00 GMT, Sept. 3, 2026)
- BIIB last close: 224.51, +0.83% (as of 20:00 GMT, Sept. 3, 2026)
- Data presented: 4-year Phase 1/2a open-label extension results at the 16th European Epilepsy Congress
- Key finding: Substantial, durable seizure reductions plus continuing cognition and behavior improvements
Frequently asked questions
What is zorevunersen being developed to treat?
Zorevunersen is an investigational medicine for Dravet syndrome, a genetic epilepsy that begins in infancy and causes frequent, difficult-to-control seizures alongside cognitive and behavioral impairment. In the studies presented, patients received zorevunersen in addition to the standard-of-care anti-seizure medicines they were already taking, rather than as a replacement for them.
What did the four-year data actually show?
Stoke Therapeutics and Biogen reported that four years of open-label extension follow-up showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior. New analyses presented at the congress also showed substantial reductions in the most severe seizure types, which clinicians regard as the leading risk factor for sudden unexpected death.
Why is an open-label extension study less definitive than a pivotal trial?
In an open-label extension, all participants receive the active drug and everyone knows it, so there is no concurrent control group. That makes the design useful for assessing durability and long-term safety, but it cannot cleanly separate the drug's effect from expectation, from changes in background medications, or from selective dropout of the sickest patients.
How did Stoke and Biogen shares respond?
Stoke Therapeutics closed at 29.99, down 1.67% from a previous close of 30.50, with a session range of 29.69 to 30.70. Biogen closed at 224.51, up 0.83% from 222.67. Both figures are the last traded prices as of 20:00 GMT on Sept. 3, 2026, with the market closed.
Was the wider market up or down that session?
Equities were broadly higher. The S&P 500 tracker closed at $773.17, up 1.05% on the day; the Nasdaq 100 proxy at $717.67, up 1.19%; and the Dow 30 tracker at $536.93, up 1.19%. Against that backdrop, Stoke's decline represented relative underperformance rather than a flat response.
What should investors watch next on this program?
The decisive items are randomized, controlled pivotal data confirming the reduction in severe seizure types, whether the cognition and behavior gains can be measured on endpoints regulators accept as evidence of disease modification, and whether the long-term safety profile holds as cumulative patient exposure extends beyond the four years now reported.
Sources
Photo: Roxanne Minnish · Pexels Licence — source


